Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant. In a 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells from a CD33-targeted cancer treatment.
Researchers used CRISPR to remove CD33 from donor stem cells, which could give doctors a way to attack aggressive blood cancers without destroying them.
In one trial in 30 patients, a modified CRISPR transplant against leukaemia saves healthy cells in the marrow. The article Leukaemia, safer marrow transplant with CRISPR cells is taken from Future Next.